Login to Your Account

Novartis in price talks in Colombia to stave off compulsory license

By Sergio Held
Staff Writer

Thursday, April 21, 2016

BOGOTA, Colombia – Novartis AG is working against the clock in Colombia in a bid to prevent the Colombian government from issuing a mandatory license for the blockbuster cancer drug Glivec (imatinib).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription